Jolanda Howe - 07 Aug 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
07 Aug 2025
Net transactions value
-$517,300
Form type
4
Filing time
08 Aug 2025, 16:50:40 UTC
Previous filing
03 Jul 2025
Next filing
23 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Howe Jolanda SVP, GLOBAL CONTROLLER C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 08 Aug 2025 0001974200

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $62,700 +10,000 +412% $6.27 12,426 07 Aug 2025 Direct
transaction MIRM Common Stock Sale $580,000 -10,000 -80% $58.00 2,426 07 Aug 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Employee Stock Option (right to buy) Options Exercise $0 -10,000 -20% $0.000000 40,000 07 Aug 2025 Common Stock 10,000 $6.27 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 16, 2024.
F2 The stock option is fully vested.